secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nutex Health Inc. (NUTX)
CIK:        0001479681
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001628280-25-052962
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nutex Health H1 2025 revenue $455.8M (+217.5% YoY), net income $3.5M, launches $25M buyback
--------------------------------------------------------------------------------

- H1 2025 revenue $455.8M (+217.5% YoY); net income $3.5M vs net loss $0.7M in H1 2024.
- Diluted EPS $0.55 (H1 2025) vs $(0.15); Adjusted EBITDA $144.4M vs $6.4M YoY.
- Q2 2025 revenue $244.0M (+220.7% YoY); net loss $17.7M includes $78.7M non-cash stock-based comp.
- Board authorized $25M stock repurchase program on Aug 14, 2025 to offset dilution.
- Net cash from operations $78.2M H1; cash balance $96.7M at June 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479681/000162828025052962/0001628280-25-052962-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479681/000162828025052962/nutx-20251118.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-052962

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer